High-grade prostatic intra-epithelial neoplasia (HGPIN) occurs a decade earlier in men of African descent in the US and Brazil, compared to white men. Prostate cancer incidence and mortality is worse in the African-American than in US white men. Sub-Saharan Africa was thought to be a low incidence area. This disparity has been attributed to lifestyle factors such as diet. We report the results of prostatic biopsies, from an ongoing national prostate cancer survey. One hundred and eleven men aged 40 y and over were recruited for medical interview (AUA symptom score), prostate specific antigen (PSA) assay and digital rectal examination (DRE). Between six and 10 cores of random digitally guided needle biopsies were performed on 24 subjects that had either suspicious prostates on digital rectal examination þ / or PSA 4 ng/ml. All lesions of the prostate were described on routine histopathology. The Gleason score and proportion of tissue involved with cancer, was determined. Eight men had benign prostatic hyperplasia (BPH), six had cancer, another six had low grade intra-epithelial neoplasia, two had HGPIN, there was one case of BPH and chronic prostatitis and one case of chronic prostatitis only. The cancer patients were aged 58 -75 y (mean 66.93 y). Gleason scores ranged from 5 to 9, there was one score of 3. Cancer made up 20 -80% tissue samples. HGPIN was found in two cases (mean age 58 y). Significant prostate cancer and the pre-cancerous lesion HGPIN exist in Dibombari, Cameroon. The purported low incidence of prostate cancer may reflect cultural and economic barriers to health care.
Introduction
High-grade prostatic intra-epithelial neoplasia (HGPIN), a premalignant lesion, is found in 0.7 -20% of all biopsies 1 and occurs about a decade earlier in men of African descent compared to white men. 2, 3 Also, prostate cancer appears to be more aggressive and also occurs at an earlier age in men of African descent in the USA. 4 The highest incidence of prostate cancer so far has been reported in Jamaican men (304/100 000). 5 The mortality rate in black men is twice that of white men (40 and 20/ 100 000, respectively). 6 The highest reported mortality from this disease occurs in people of African descent from the Caribbean islands of St Vincent and Bermuda. 7 It has therefore been stated that prostate cancer, in men of African descent is different from that of other races. Although yet to be proven, high tumor cell proliferation and a block to programmed cell death (apoptosis) as measured by the major anticell death gene bcl-2, may explain the high virulence of prostate cancer in black men. 8 Few studies have been done in indigenous Africans, in sub-Saharan Africa. To date, reports from the region have usually been hospital-based, and have dealt largely with urban populations. African populations on the continent were considered to be of low risk for prostate cancer. In particular, the rural Bantu African, it was alleged, rarely developed prostate cancer. A short life expectancy, a diet high in fiber and low in fat, and liver disease seemed to protect the rural Bantu man from getting prostate cancer. 9, 10 Herein we report on the prevalence of HGPIN and prostate cancer; in Dibombari, a rural district of Cameroon.
Methodology Site
Dibombari is a district of the Littoral province of Cameroon with a total population of 37 577, and a male population of 18 037; 3066 (16.7%) of whom are 40 y and older. Ninety per cent of its inhabitants were classified as rural during the last census, and consume a traditional diet of cassava, high in fiber. There is precious little intake of fat and processed foods.
Subjects
Men 40 y and over living in the district were invited to participate in the survey.
Procedure
Two epidemiologists numbered all the homes in the district. Households were selected for participation using systematic sampling. 11 The survey instruments consisted of a household questionnaire with questions on vital statistics, lifestyle and diet, responded to by the head of the household. A second questionnaire had questions on occupation, smoking, alcohol intake and history of hypertension or diabetes, answered by each participant. A third form contained questions on irritative and obstructive voiding symptoms, hematuria, sexually transmitted disease, answered by each individual. Each participant's blood pressure was taken, and glucosuria and proteinuria were tested using the Ames urostix. Ten milliliter aliquots of venous blood were drawn, and centrifuged to decant serum, which was frozen. The serum was shipped in dry ice to The Pacific Northwest Foundation Hospital in Seattle, for prostate specific antigen (PSA), prostate membrane specific antigen (PMSA) and free-prostate specific antigen (f-PSA) determinations. The Hybritech assay technique for these tests has been described before. 12 The urologist (FFA) performed a digital rectal examination (DRE) and bimanual pelvic examination in the dorsal lithotomic position. Individuals with an abnormal DRE and/or PSA result were invited later for a prostate biopsy.
Biopsy procedure
Biospy was performed following informed consent during which invited cases were explained the risks and benefits of biopsy, including bleeding, infection and urinary retention. They took 400 mg of norfloxacin orally an hour before the biopsy, and twice daily for one week. Those who chose to be biopsied were re-examined in the dorsal lithotomic position. After a betadine povidine scrub of the perineum, 200 mg of aqueous xylocaine was infiltrated along a tract from perineal skin onto the prostate (digitally directed transperineal biopsy). Using the multiple biopsy gun (MBG), loaded with a 16 cm 18 gauge biopsy needle, six to 10 digitally directed cores of prostate tissue were removed. To decrease false negative biopsy outcomes, the number of biopsy samples was increased to as much as 10 for large glands. Because ultrasound was not available, transition zone biopsies were not identified, however laterally directed biopsies were consistently retrieved. Additionally, any palpable nodules were also biopsied. In normal prostates with elevated PSA, and normal areas in prostates bearing nodules, six to 10 cores of tissues were randomly obtained. All tissue specimens were fixed in 10% formalin liquid stored in 2 ml cryotubes. These tubes were transported to the pathology laboratory, at The Medical College of Ohio, for histopathological examination. The formalin-fixed tissue was mounted in paraffin blocks and processed for routine histopathology. The pathologist (AZ) examined all the biopsy specimens for cancer and HGPIN, and the percentage of the biopsy sample involved with cancer. Tumor differentiation was estimated using the Gleason score.
Results
Eighteen households were selected for the survey. Among the 36 men who were expected from these homes, 34 participated. A total of 111 men were examined since 77 uninvited men attended the survey. Seventy-one (63.96%) men were asymptomatic or had mild symptoms (AUASS 7), 28 (25.23%) had moderate symptoms (AUASS > 7 < 20), and 12 (10.81%) had severe lower urinary tract symptoms (AUASS > 19).
DRE scoring
Thirty-seven (38.95%) men who had normal and unenlarged prostates were scored as group 1, 25 (26.32%) with suspicious glands (hard, nodular, irregular, and or fixed), were scored as group 2, and 33 (34.74%) men, with an enlarged gland, benign in consistency, were scored as group 3. The invited and uninvited subgroups were different vis-à-vis DRE results, P ¼ 0.036.
PSA results
Thirteen men either refused to donate blood for PSA determination or had insufficient quantities of serum. Of the 98 patients with PSA results, 14 (14.29%) had PSA levels 4 ng/ml and one other had an age-adjusted abnormal PSA (a 43-y-old with a PSA of 3.74 ng/ml). A total of 15 men (15.30%) therefore, in this community had abnormal PSA results. Nine of the 15 men were biopsied. Six had cancer, three had BPH. PSA was elevated in one third of men without prostate cancer and in all men with prostate cancer. On the other hand, PSA was normal ( < 4 ng/ml) in subjects with HGPIN and LGPIN.
Biopsy
Thirty-nine men who had abnormal PSA and or DRE were invited for biopsy. Only 24 of the 39 (nine of 34 invited and 30 of 77 uninvited) patients participated. Of the 34 invited cases, three had cancer giving 8.6% prevalence. Seven men had died between the survey and the biopsy sessions, one from a dog bite and six from unspecified illnesses. One man had moved from the area. Fifteen men did not come for biopsy. The most common histological lesion was benign prostatic hypertrophy (eight men), followed by low-grade prostatic intra-epithelial neoplasia (six men) and cancer of the prostate in six men (25%). High-grade prostatic intra-epithelial neoplasia (HGPIN) was found in two patients (8.3%) ( Table 1) . 
Comment
Sub-Saharan Africa is regarded as a low incidence area for prostate cancer. Most of the studies that led to this conclusion were hospital-based or at best culled from tumor registries in pathology departments. The flaws from such studies are evident as the numerator and denominator were usually unknown. The situation was further aggravated by limited access to standard diagnosis and care, no population statistics and the absence of health coverage for the poor. The poor, rural Bantu, who was not recruited in sufficient numbers in hospital-based studies was assumed to have a diminished risk for prostate cancer. This randomized population study suggests that prostate cancer incidence is higher than reported in hospital-based series. Some hospital-based reports, carried out by clinicians, however suggested that prostatic diseases including cancer were common in the Bantu. 9,10,13 -15 Prostate cancer was found in 15% of Bantu patients who presented principally with urinary retention. 9 Further, most of these patients had advanced disease. The method of the present study corrected for biases (cultural and financial-access) of hospital-based studies. With a greater than 50% rate of participation, it is unlikely that those invited men who did not turn up and the uninvited who showed up had different risks for prostate cancer. The presence of cancer in six men and HGPIN in two from this rural population, that consumes a low-fat, high-fiber traditional African diet, rekindles the debate on the role of diet in prostate cancer epidemiology.
There has been a tendency to assume that cancer detected from screening in the population is not life threatening disease, and may be latent. PSA-driven screening population studies have detected principally localized cancers as opposed to regional or metastatic cancers. 16 The question as to whether early detection of localized prostate cancer diminishes mortality may only be answered several decades after the PSA-detected cancer era. All but one of the cancers in this study had Gleason scores between 5 and 9. Further, the tumor burden (volume of cancer) ranged from 20 to 80% of the biopsy material submitted for study, suggesting that these were significant cancers.
A screening exercise in populations where there is no access to care is likely to detect all stages and types of cancer. The high prevalence of (high grade) cancer and HGPIN, suggests that in sub-Saharan populations, where there is a dearth of urologic care, screening for prostate cancer may be necessary. The true impact of treatment and other post-biopsy events on survival and mortality from prostate cancer is likely to be better evaluated in this population where financial incentives are not tied to treatment regimens or techniques.
An 8% prevalence of HGPIN in this study is significant. It is the first time, to our knowledge, that this lesion has been reported in a sub-Saharan population. In other areas, it is reported in between 4 and 5% of prostatic biopsies. 17 HGPIN is a premalignant lesion, for in patients with HGPIN only a carcinoma is found in as many as 50% of them on a second biopsy within 1 y. 18, 19 The incidence of cancer in second biopsies is variable but it has been shown to be greater in patients with atypical glands 20 More interestingly, it is said that as cancer develops in the prostate, it replaces HGPIN. 21 It seems therefore that the severity of the prostatic condition starts with HGPIN alone, progresses as HGPIN and cancer, and finally cancer alone overwhelms the gland.
The expression of proto-oncogenes, multiple genetic changes, aneuploidy, diminished expression of tumor suppression genes and high concentration of cellular proliferation markers in HGPIN, are evidence that it is a lesion closely associated with poorly-differentiated carcinoma as opposed to well-differentiated tumors. HGPIN therefore is important in neoplastic progression and has been considered a bona fide target or marker for chemoprevention. 20 HGPIN and computer-assisted image analysis of dysplastic lesions on histology are surrogate endpoints such that diagnosis of HGPIN and associated putative pre-malignant lesions alone in biopsy samples is an indication for chemoprevention. The possibility of chemopreventive therapy arresting cancer growth, offers a potential public health breakthrough, 22 and strengthens the argument for screening and early detection.
Cancer chemoprevention strategies are predicated on the ability of natural and or synthetic agents to inhibit, reverse, or modulate the evolution from normal to precancer and from precancer to cancer. Subjects at high risk for cancer development (positive family history, subjects with elevated PSA/negative biopsy, and subjects with HGPIN/negative biopsy) have been enrolled in the Prostate Cancer Prevention Trial/Selenium and Vitamin E Chemoprevention Trial (PCPT/SELECT). Other potential chemoprevetion agents include antiandrogens, antiestrogens, phytoestrogens, antioxidants, anti-inflammatory (proapoptotic) agents, antiproliferation/antidifferentiation agents, signal transduction modulators of receptor tyrosine kinase and ras farnesylation, antiangiogenesis agents, insulinlike growth factor (IGF)-1, peroxisome proliferator-activator receptor modulators (gamma and delta), and gene-based interventions. 23 This study also shows clearly that PSA has an important role in the detection of prostate cancer in sub-Saharan Africa. PSA correlation with prostate histopathology in this population is similar to that of the African-American in Detroit. 24 This brings into focus the debate on new technologies, their costs and their use in poor and well to do communities alike. Whether the determination of serum free PSA and PSMA in addition to total PSA assay, improves upon the cost effectiveness of cancer detection is still debated. 12,25 HGPIN in, and of itself, is not responsible for elevated serum PSA. This observation underscores the need to perform DRE even in this PSAdriven prostate cancer detection era, especially if the chemopreventive therapy of HGPIN may arrest cancer development. 26 Whereas age is not an independent variable for prostate cancer risk, it is an important co-variable especially when race is considered. Several studies suggest that prostate cancer occurs at a younger age in people of African descent. 2, 4, 27 This has also been shown to be the case with the precancerous lesion HGPIN. Its incidence is greater in the black race. 28 It has also been shown to occur a decade earlier in African-American men than in Caucasians. 3 In Brazil, HGPIN was found a decade earlier in African-Brazilians than in white Brazilians. 2 Indeed, the mean age at which HGPIN was detected in this study was 8 y earlier than the mean age of patients with prostate cancer.
Conclusion
HGPIN and prostate cancer were detected in a rural area (Dibombari) of Cameroon. The tumor volume and differentiation suggested that this was clinically significant disease.
The age-adjusted prevalence of 195 69/100 000 men for prostate cancer in this rural population suggests that the high prevalence of prostate cancer in sub-Saharan Africa is not necessarily linked to urbanization (Western diet) itself. The detection of HGPIN, a precancerous lesion, implies that prostate cancer burden (morbidity and mortality) can be controlled in this population, because HGPIN is potentially an indication for prostate cancer chemoprevention therapy. If chemopreventive therapy were to decrease the incidence, morbidity and mortality of prostate cancer, then screening and early detection trials would be justified. This study further challenges the designation of rural sub-Saharan populations as low risk for prostate cancer.
